Loading...

Crinetics Pharmaceuticals

DB:6Z4
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6Z4
DB
$582M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
6Z4 Share Price and Events
7 Day Returns
7.1%
DB:6Z4
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-
DB:6Z4
-7.4%
DE Biotechs
-5.6%
DE Market
6Z4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Crinetics Pharmaceuticals (6Z4) 7.1% 5% 6.3% - - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • No trading data on 6Z4.
  • No trading data on 6Z4.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Crinetics Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Crinetics Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €21.485.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Crinetics Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Crinetics Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6Z4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.23
NasdaqGS:CRNX Share Price ** NasdaqGS (2019-04-24) in USD $24.17
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Crinetics Pharmaceuticals.

DB:6Z4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CRNX Share Price ÷ EPS (both in USD)

= 24.17 ÷ -2.23

-10.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Crinetics Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Crinetics Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Crinetics Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:6Z4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-27.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Crinetics Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Crinetics Pharmaceuticals's assets?
Raw Data
DB:6Z4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.66
NasdaqGS:CRNX Share Price * NasdaqGS (2019-04-24) in USD $24.17
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:6Z4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CRNX Share Price ÷ Book Value per Share (both in USD)

= 24.17 ÷ 6.66

3.63x

* Primary Listing of Crinetics Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Crinetics Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Crinetics Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Crinetics Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Crinetics Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-27.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Crinetics Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Crinetics Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Crinetics Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Crinetics Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6Z4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6Z4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -27.7%
DB:6Z4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts -87.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6Z4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6Z4 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -109 -134 3
2022-12-31 0 -93 -113 3
2021-12-31 0 -74 -83 4
2020-12-31 0 -56 -64 5
2019-12-31 1 -38 -44 5
DB:6Z4 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -19 -27
2018-09-30 2 -16 -21
2018-06-30 2 -13 -16
2018-03-31 2 -11 -12
2017-12-31 2 -9 -9
2016-12-31 1 -5 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Crinetics Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Crinetics Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6Z4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Crinetics Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6Z4 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.61 -2.95 -4.70 3.00
2022-12-31 -3.35 -2.66 -4.25 3.00
2021-12-31 -2.78 -2.36 -3.35 4.00
2020-12-31 -2.36 -2.02 -2.83 5.00
2019-12-31 -1.77 -1.61 -1.95 4.00
DB:6Z4 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.23
2018-09-30 -3.27
2018-06-30 -8.96
2018-03-31 -7.81
2017-12-31 -6.68
2016-12-31 -5.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Crinetics Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Crinetics Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Crinetics Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Crinetics Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Crinetics Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Crinetics Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Crinetics Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Crinetics Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Crinetics Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Crinetics Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6Z4 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.43 -27.12 6.66
2018-09-30 2.18 -21.14 4.57
2018-06-30 2.27 -15.94 3.32
2018-03-31 2.44 -12.02 2.60
2017-12-31 2.05 -9.16 1.94
2016-12-31 0.59 -6.02 1.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Crinetics Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Crinetics Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Crinetics Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Crinetics Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Crinetics Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Crinetics Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Crinetics Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Crinetics Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Crinetics Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Crinetics Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Crinetics Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Crinetics Pharmaceuticals Company Filings, last reported 3 months ago.

DB:6Z4 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 160.23 0.00 163.88
2018-09-30 167.52 0.00 169.65
2018-06-30 67.80 0.00 68.41
2018-03-31 73.00 0.00 73.74
2017-12-31 14.68 0.00 14.19
2016-12-31 11.54 0.21 12.15
  • Crinetics Pharmaceuticals has no debt.
  • Crinetics Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Crinetics Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Crinetics Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 55.1% each year.
X
Financial health checks
We assess Crinetics Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Crinetics Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Crinetics Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Crinetics Pharmaceuticals dividends.
If you bought €2,000 of Crinetics Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Crinetics Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Crinetics Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6Z4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6Z4 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Crinetics Pharmaceuticals has not reported any payouts.
  • Unable to verify if Crinetics Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Crinetics Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Crinetics Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Crinetics Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Crinetics Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Crinetics Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Crinetics Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
R. Struthers
COMPENSATION $385,522
AGE 56
TENURE AS CEO 10.3 years
CEO Bio

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in 2008 and serves as its Chief Executive Officer and President since December 2008. Prior to Crinetics, Dr. Struthers served as Senior Director and Head, Endocrinology and Metabolism at Neurocrine Biosciences. At Neurocrine, he initiated and led its efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, which has demonstrated safety and efficacy in over 40 clinical trials totaling more than 3,000 patients. Prior to Neurocrine, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. He serves as a Director at Crinetics Pharmaceuticals, Inc. Dr. Struthers is an author of more than 75 scientific publications. He holds Ph.D. in Physiology and Pharmacology from the University of California, San Diego.

CEO Compensation
  • Insufficient data for R. to compare compensation growth.
  • R.'s remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Crinetics Pharmaceuticals management team in years:

1.3
Average Tenure
55
Average Age
  • The average tenure for the Crinetics Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

R. Struthers

TITLE
Founder
COMPENSATION
$386K
AGE
56
TENURE
10.3 yrs

Marc J. Wilson

TITLE
CFO & Secretary
AGE
39
TENURE
1.3 yrs

Alan Krasner

TITLE
Chief Medical Officer
AGE
55
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Crinetics Pharmaceuticals board of directors in years:

2.4
Average Tenure
56
Average Age
  • The average tenure for the Crinetics Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Wendell Wierenga

TITLE
Chairman of the Board
AGE
70
TENURE
3.5 yrs

R. Struthers

TITLE
Founder
COMPENSATION
$386K
AGE
56
TENURE
10.4 yrs

Steve Kaldor

TITLE
Director
AGE
56
TENURE
3.5 yrs

Matt Fust

TITLE
Director
AGE
53
TENURE
1.2 yrs

David Clemmons

TITLE
Member of Scientific Advisory Board

Mason Freeman

TITLE
Director
AGE
67
TENURE
3.5 yrs

Anne Klibanski

TITLE
Member of Scientific Advisory Board
AGE
66
TENURE
2.4 yrs

Weston Nichols

TITLE
Director
AGE
32
TENURE
1.2 yrs

Jack Nielsen

TITLE
Director
AGE
54
TENURE
1.2 yrs

Philip Harris

TITLE
Member of Scientific Advisory Board
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 19 Sell Vivo Capital, LLC Company 20. Mar 19 20. Mar 19 -417,000 €19.60 €-8,171,355
20. Mar 19 Sell 5AM Venture Management LLC Company 18. Mar 19 18. Mar 19 -154,839 €21.39 €-3,312,621
25. Jan 19 Sell 5AM Venture Management LLC Company 22. Jan 19 22. Jan 19 -262,153 €19.26 €-5,048,166
27. Aug 18 Buy Perceptive Advisors LLC Company 18. Jul 18 18. Jul 18 307,648 €18.29 €5,628,288
20. Jul 18 Buy 5AM Venture Management LLC Company 20. Jul 18 20. Jul 18 115,000 €14.52 €1,669,766
27. Aug 18 Buy Perceptive Advisors LLC Company 20. Jul 18 20. Jul 18 400,000 €14.52 €5,807,880
20. Jul 18 Buy Vivo Capital, LLC Company 20. Jul 18 20. Jul 18 353,180 €17.71 €5,616,067
20. Jul 18 Buy Alan Krasner Individual 20. Jul 18 20. Jul 18 2,000 €14.52 €29,039
X
Management checks
We assess Crinetics Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Crinetics Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing’s diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Details
Name: Crinetics Pharmaceuticals, Inc.
6Z4
Exchange: DB
Founded: 2008
$520,363,564
24,095,485
Website: http://www.crinetics.com
Address: Crinetics Pharmaceuticals, Inc.
Building 2,
10222 Barnes Canyon Road,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CRNX Common Stock Nasdaq Global Select US USD 18. Jul 2018
DB 6Z4 Common Stock Deutsche Boerse AG DE EUR 18. Jul 2018
Number of employees
Current staff
Staff numbers
48
Crinetics Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:41
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.